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Gap junctions and their connexin components are indispensable in mediating the cellular coordina-
tion required for tissue and organ homeostasis. The critical nature of their existence mandates a
connection to disease while at the same time offering therapeutic potential. Therapeutic interven-
tion may be offered through the pharmacological and molecular disruption of the pathways
involved in connexin biosynthesis, gap junction assembly, stabilization, or degradation. Chemical
inhibitors aimed at closing connexin channels, peptide mimetics corresponding to short connexin
sequences, and gene therapy approaches have been incredibly useful molecular tools in deciphering
the complexities associated with connexin biology. Recently, therapeutic potential in targeting
connexins has evolved from basic research in cell-based models to clinical opportunity in the form
of human trials. Clinical promise is particularly evident with regards to targeting connexin43 in the
context of wound healing. The following review is aimed at highlighting novel advances where the
pharmacological manipulation of connexin biology has proven beneﬁcial in animals or humans.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Evolution of the multi-celled organism demanded the coordi-
nated integration of cell types and the intricate orchestration of
the processes involved in cell coordination, synchronization,
growth, differentiation, and programmed cell death. The formation
of channels that directly link the cytoplasm of adjacent cells (gap
junctions) or permit cell-extracellular communication (hemichan-
nels), encoded by a set of highly evolutionarily conserved genes
(connexins), appears ingeniously simple when considering the
complex biology of the higher functioning organism. Scientiﬁc
literature reveals the essential roles of these processes in cell and
tissue homeostasis and angiogenesis, and by default, in a slew of
pathological processes [1–3]. Research aimed at disclosing the
dynamic, cell and disease speciﬁc roles involved in connexin tran-
scription, translation, turnover, trafﬁcking, and dysfunction barely
scrape the surface in terms of deciphering the complexities associ-
ated with translating connexin biology to therapeutic opportunity.
In reviewing the clinical promise associated with connexins, it
seems best to keep in mind a quote by HL Mencken: ‘‘For everycomplex human problem, there’s a solution that is simple, neat,
and wrong. . ..’’.
The canonical connexin is diagrammed as a tetraspan trans-
membrane protein with two extracellular loops, a cytoplasmic
loop, and a cytoplasmic amino and carboxyl-terminus (N- and
C-terminus). Six connexins oligomerize to form cored connexon
transmembrane channels that couple with connexons on neigh-
boring cells to form intercellular channels, which in turn aggregate
to form gap junctions (GJs) [4,5]. Hemichannel recruitment to the
preexisting GJ plaque is a critical determinant in the operational
area, size, and stability of GJs [6]. The formation and dissolution
of hemichannels and GJs is dynamic and regulates both junctional
and non-junctional intercellular communication. It has been over
half a century that the physiological relevance of these processes
was ﬁrst appreciated in studies that examined the electrical trans-
mission of signals at the giant motor synapses in the crayﬁsh [7].
We now know that intercellular communication is key in numer-
ous processes critical for biological homeostasis including, but
certainly not limited to, the rapid transmission of action potentials
in heart and neuronal tissues [8–10], and the diffusion of metabo-
lites, nucleotides, nutrients, and second messengers with roles in
apoptosis, gene expression, inﬂammatory responses and cellular
growth [11–28]. An additional level of complexity is bestowed
in situations where heteromeric assembly of different connexin
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physical properties rendering preference with regard to passaging
molecules [29,30].
Therapeutic intervention may be offered through the pharma-
cological and molecular disruption of the pathways involved in
connexin biosynthesis, GJ assembly, stabilization, or degradation
[31]. Chemical inhibitors aimed at closing connexin channels, pep-
tide mimetics corresponding to short connexin sequences, and
gene therapy approaches have been incredibly useful molecular
tools in deciphering the complexities associated with connexin
biology (Fig. 1). The therapeutic potential of these tools has only
recently been evaluated in clinical trials. The following review will
focus on discussing the translational relevance and clinical poten-
tial underlying the pharmacological manipulation of connexin
biology.
2. Lessons learned from wound healing
The role of connexins in maintaining tissue homeostasis offers
important lessons in both the scientiﬁc and commercial
exploration of connexin–based therapeutics. A wide range of
inherited human disorders stem frommutations in connexin genes
(Table 1; reviewed in detail in [32,33]), highlighting the indispens-
able role of GJs in normal tissue function. Of the twenty-one
identiﬁed connexin isoforms in the sequenced human genome,
the epidermis expresses at least 10, including Cx26, Cx30, Cx30.3,
Cx31.1, and Cx43, each correlated with a uniquely dynamic spatial
and temporal expression pattern and functional role [34–37]. Gi-
ven that the coordination and progression of wound healing and
re-epithelialization is tied to a complex series of events that occur
between various cell types, extracellular matrix components and
signaling molecules, the critical role of connexins in regulatingFig. 1. Connexin-based therapeutics target both gap junctions and hemichannels through
Cx43 junctional complex generated from confocal optical sections of standard Cx43 imm
s Standard Cx43 immunoﬂuorescence highlights gap junctions, which are composed
coupling by improving conduction in the heart or spatial buffering in the brain, for examp
of diffuse hemichannelsv. Hemichannels are generally reduced in number or closed by c
cell death signaling, and purinergic signaling of inﬂammatory cells.w Both intercellular
has a cytoplasmic N-terminus (NT), 4 transmembrane domains, 2 extracellular loops (EL1
indicate regions of the primary sequence that have been used to (or could be used to)
peptides of the ﬁrst and second extracellular loops respectively, and Gap19 is derive
endogenous peptide discovered by Smyth and Shaw [177], and PEP-1 and PEP-2 mim
contains numerous phosphorylation sites that act as molecular switches for Cx43 dysrethe metabolic coupling between cells and transfer of cell signaling
molecules during the cutaneous injury response is palpable. These
include roles in leukocyte diapedesis, re-epithelialization, wound
contraction, ﬁbroblast function, and collagen deposition and syn-
thesis [38,39].
2.1. Connexin43 and therapeutic opportunity
The translational bridge connecting connexins to wound heal-
ing therapeutics was ﬁrst made readily apparent with Cx43, the
most highly expressed and widely studied connexin in human skin
[39–42]. Experiments in murine wound models describe the tran-
sient expression pattern of Cx43 and GJ intercellular communica-
tion at the wound periphery following dermal injury. Following
injury, Cx43 in the wound edge slowly downregulates over approx-
imately 48 h, during which time keratinocytes adopt a migratory
phenotype [37,39–42]. These same studies show that Cx43 down-
regulation is correlated with increased levels of TGF-b mRNA and
collagen a-1, and decreased levels of chemokine ligand-2, tumor
necrosis factor alpha (TNFa), inﬁltrating neutrophils and macro-
phages at the wound site, as well as the promotion of angiogenesis,
ﬁbroblast migration, and keratinocyte proliferation. Conversely,
Cx43 expression is elevated in the blood vessels proximal to the
wound site, with another rise several days post-wounding during
granulation formation. The post-translational phosphorylation of
serines (S364, S365, S325, S328, S330, S368, S279, S282, S262) in
the C-terminal domain of Cx43 during these processes contributes
to conformational changes and the formation or disruption of GJs
and GJ intercellular communication depending on the site
phosphorylated [43–46]. Additionally, Cx43 hemichannels release
molecules such as glutamate, ATP, NAD+, prostaglandin E2, and
glutathione, providing a paracrine route for intercellularmultiple domains on the Cx43 subunit.r A three dimensional reconstruction of the
unoﬂuorescences, and Cx43-Cx43 Duolink (Olink Bioscience, Uppsala, Sweden)t.
of aggregated intercellular channels u. Drug targets may inﬂuence intercellular
le.t Duolink imaging of Cx43 enables imaging of the perinexus, which is composed
onnexin-based therapeutics as their opening in pathological systems participates in
channelsu and hemichannelsv are oligomers of connexin subunits. Each subunit
and EL2), a cytoplasmic loop (CL), and a cytoplasmic C-terminus (CT). Yellow areas
generate connexin-based therapeutics. Speciﬁcally, Gap26 and Gap27 are mimetic
d from the cytoplasmic loop [158]. ACT-1 mimetic peptide [25,64–66,96,99], the
etic peptides [173] are all found on the C-terminus. Furthermore, the C-terminus
gulation in injury.
Table 1
Connexin associated genetic diseases.
Human disease Clinical manifestation Connexin
protein
Myelin-related diseases
X-linked charcot-Marie-Tooth disease
(CMTX)
Limb weakness; progressive demyelination of peripheral axons Cx32
Pelizaeus-Merzbacher-like disease (PMLD) Mild peripheral neuropathy Cx46
Cx47
Cardiovascular disease
Idiopathic atrial ﬁbrillation Atrial arrhythmia and congestive heart failure Cx40
Visceroatrial heterotaxia Heart malformations and visceral organ defects Cx43
Skin diseases
Vohwinkel syndrome Palmoplantar keratoderma with ichthyosis and hearing loss Cx26
Keratitis-ichthyosis-deafness syndrome
(KID)
Vascularizing keratitis with hyperkeratotic skin lesions and hearing loss Cx26
Cx30
Erythrokeratoderma variabilis (EKV) Slow growing erythematous patches and static keratodermas; deafness w/Cx31 mutation Cx30
Cx30.3
Cx31
Clouston’s hidrotic ectodermal dysplasia Hypotrichosis, palmoplantar keratoderma, nail dystrophy, and/or hyperpigmentation Cx30
Psoriasis Hyperproliferation of epidermal keratinocytes resulting in scaly, reddened skin patches, papules and
plaques
Cx26
Hystrix-like icthyosis with deafness (HID) Severe ichthyosis and hearing loss Cx26
Bart-pumphrey syndrome Hyperkeratosis over the metacarpophalangeal and proximal and distal interphalangeal joints and
hearing loss
Cx26
Non-syndromic and syndromic deafness Sensorineural hearing loss; and in syndromic (associated with hyperproliferative skin disorders) Cx26
Cx30
Cx31
Cx43
Zonular pulverulent cataracts Congenital cataracts Cx46
Cx50
Oculodentodigital dysplasia (ODDD) Pleiotropic developmental disorder: includes ophthalmologic, dental, craniofacial, bone and limb
disorders
Cx43
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sponses that serve to coordinate wound repair and regulate neu-
trophil inﬁltration and ﬁbroblast proliferation [18–28].
Studies aimed at genetically and molecularly targeting Cx43
have set the stage for the clinical development of connexin-based
therapeutics. Kretz et al., demonstrated that Cx43-gene knockout
mice had a faster rate of wound closure as compared to wild-type
animals, suggesting that reductions in keratinocyte GJ intercellular
communication is required for efﬁcient mobilization and migration
[47]. Similarly, topical application of a Cx43 antisense oligonucleo-
tide (Cx43asODN) to incisional and excisional wounds accelerated
Cx43 downregulation, resulting in enhanced wound healing, re-
duced neutrophil, macrophage, and leukocyte inﬁltration, and the
reduction in overall area of granulation tissue formation [39,40].
These results were extended to reductions in scarring in murine
neonate burn wounds and in enhanced reepithelialization of
wounds in diabetic rat models [48,49]. Accelerated healing at skin
wound sites was associated with increased TGF-b1 mRNA and col-
lagen content, and a reduction in the mRNA levels of CC chemokine
ligand 2 and TNF-a suggesting that an anti-inﬂammatory milieu is
essential for improved healing [40].
Clinical efﬁcacy has been indicated in randomized trials evalu-
ating the potential of Cx43asODN in a thermo-reversible, slow re-
lease pluronic gel formulation (Nexagon™) in accelerating the
closure of chronic venous stasis ulcers and diabetic foot ulcers
(CoDa Therapeutics Inc., http://www.codatherapeutics.com). Cur-
rent efforts of this group include the generation and optimization
of bioactivated alginate microspheres coated with a pluronic gel
containing their Cx43 antisense. Potential applications may in-
clude use as a dermal substitute [50]. Company reports indicate
clinical safety and efﬁcacy of Cx43asODN, however, as with any
therapeutic approach predicated on gene silencing, targeting con-
nexins with a wide-spectrum antisense designed to universally
knock down activity may be associated with therapeutic risks
including delivery and efﬁcacy issues, off-target effects, and a high-
er probability of generating adverse physiological effects [51].Connexin mimetic peptides corresponding to short speciﬁc se-
quences that directly interact with connexin extracellular loop do-
mains offer speciﬁc and reversible modulation of gap-junctional
communication (Fig. 1). As compared to pharmacological GJ block-
ers, peptide mimetics likely depend on GJ turnover and act more
slowly. Early electrophysiological studies using aortic smooth
muscle cell models and peptide mimetics of Cx40 and Cx43 sug-
gested that connexin mimetic peptides do not disrupt GJ biogene-
sis, but directly impact channel gating [52,53]. Recent reports
conﬁrm that connexin peptide mimetics effectively block hemi-
channel opening and prevent hemichannel docking to form gap
junctions without affecting their structure [54–56]. The utility of
such peptides in unraveling the molecular mechanisms underlying
epidermal morphogenesis is evident in a series of elegantly
designed 3D living skin equivalent models where attenuation of
Cx43-mediated communication via the use of mimetic peptides
directly enhanced wound-closure [57].
Given the high degree of conservation in the extracellular loop
of connexin isoforms the most commonly used connexin peptide
mimetics, Gap26 and Gap27, are promiscuous, thus potentially
hindering clinical development. These peptides were originally
created to bind to the extracellular loop of cells displaying hemi-
channels, and mimic the docking of that hemichannel with another
[58]. The intended effect was to open the hemichannel by simulat-
ing intercellular channel formation, but instead, the peptides are
well documented to close hemichannels and block intercellular
channel formation [59]. Based on studies that examined the time-
frame for inhibition of hemichannels vs GJ channels, which demon-
strated that hemichannels are blocked by Gap26 within 2–3 min
while GJs require 30 min of exposure [59], it has been suggested
that Gap26 and Gap27 do interact with the extracellular loops of
hemichannels resulting in blockage of the channel pore followed
by prevention of GJ channel formation, effectively inhibiting GJ
communication [60]. It is important to consider that these peptides
may have secondary effects through changes in Cx43 phosphoryla-
tion [61]. In wound healing models using normal human ﬁbroblast
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hanced cell migration and proliferation, without altering Cx43 pro-
tein levels [62]. However, these results could not be extended to
in vitro diabetic cell models [61]. Gap junction blockers represent
helpful molecular tools in deﬁning gap junction function, but it is
quite difﬁcult to consider them as therapeutic drugs due to their
non-speciﬁcity and potential side effects.
Therapeutic opportunity was discovered with a distinct Cx43
mimetic when a unique molecular tool designed to disrupt the
interaction between Cx43 with its binding partner zonula occlu-
dens (ZO-1) was found to affect NIH-3T3 ﬁbroblast migration in
2D scratch assays. ACT1 (alpha-connexin carboxyl-terminal pep-
tide 1) is a synthetic peptide incorporating the C-terminal ZO-1
binding domain of Cx43 (RPRPDDLEI) linked at it N-terminus to
an antennapedia penetration sequence (RQPKIWFPNRRKPWKK)
to enable cell entry [63,64]. ZO-1 binding of the Cx43 C-terminus
is directly linked to changes in cellular communication and gap
junction remodeling during the process of wound healing [65].
Application of ACT1 in in vivo wound healing and ischemic cardiac
injury studies indicated anti-inﬂammatory, anti-ﬁbrotic, and tissue
regenerative properties via GJ intercellular communication stabil-
ization [42,64,66–68]. In murine skin and pig wound models,
reductions in neutrophil inﬁltration and rate of wound closure
were similar as to those reported with Cx43asODN [64].
ACT1’s method of action with regards to tissue regeneration and
the dampening of inﬂammatory responses is independent of Cx43
expression. ACT1 has a high binding speciﬁcity with the PDZ-2 do-
main of ZO-1 and competitively inhibits the interaction of Cx43
and ZO-1, which mediates increases in GJ size and stability with
concomitant reductions in hemichannels [25,63,69]. As such, ZO-
1 regulation of the cellular distribution of Cx43, and modulation
of ZO-1’s action provides a control point for dynamic switching be-
tween gap junctional communication and hemichannel communi-
cation [25]. By blocking Cx43/ZO-1 interaction, ACT1 favors
enhanced GJ intercellular communication while reducing Cx43
hemichannel activity [25]. Molecular deciphering of ACT1’s mech-
anism of action additionally reveals potential interaction with
CCN3 – a matricellular protein implicated in glioma and tissue-in-
jury response [70], 14-3-3 proteins [71], SH3-mediated interac-
tions [72], various protein kinases [46], and with the cytoplasmic
loop domain of Cx43 [73]. The functional consequences included
an increase in the coordination of cellular communication, tem-
pered inﬂammatory responses, enhanced wound re-epithelializa-
tion and reductions in the formation of excess ﬁbrous connective
tissue [25,42,64], suggesting therapeutic potential.
Similar results have been obtained in studies evaluating the im-
pact of ACT1 incorporation into silicone implants which reported
the attenuation of neutrophil inﬁltration, increased vascularity of
the capsule tissue, reduced type I collagen deposition around the
implant, and reduced persistence of contractile myoﬁbroblasts
[65]. The similarities to the effects of ACT1 in the skin are not sur-
prising given that the foreign body response is a modiﬁed version
of cutaneous wound healing [65]. These results suggest therapeutic
opportunity for ACT1 as an enabling technology for modulating the
wound-healing response to implants via promoting integration of
implanted materials and tissue-engineered devices in the human
body [74].
A topical formulation of ACT1 (Granexin™ Gel; FirstString
Research Inc., http://ﬁrststringresearch.com) has been carried
through four efﬁcacious human clinical trials, including a Phase I
clinical study to evaluate dose range, safety, and efﬁcacy in pro-
moting faster healing and scar reduction in full-thickness punch
biopsy wounds; and three Phase 2 human clinical trials for the
treatment of chronic diabetic foot ulcers, venous leg ulcers, and
the reduction of scar formation in surgical incision wounds
following laparoscopic surgery (http://online.wsj.com/article/PR-CO-20130715-904787.html?mod=googlenews_wsj). ACT1
application signiﬁcantly accelerated the closure of chronic wounds,
reduced scarring, and was not associated with immunogenicity or
local or systemic drug-related adverse events. Pre-clinical toxicity
studies reported clinical signs following intravenous administra-
tion of ACT1 atP10 mg/kg (Maximum Tolerated Dose), suggesting
that systemic administration of ACT1 is available in other injury
types where topical administration is not feasible (e.g. ischemic
brain injury). Therapeutic promise is further supported by animal
toxicology studies reporting that the clinical symptoms associated
with high doses of ACT1, including piloerection, decreased activity,
wobbly gait, prostration, and breathing abnormalities, were typi-
cally short in duration and resolved within 24 h. Clinically speak-
ing, the relatively mild and reversible nature of these symptoms
is encouraging but is likely linked to short half-life of the peptide.
Whilst sufﬁcient for dermal application protocols as pertaining to
wound healing, applications requiring extended delivery of conn-
exin-based peptide mimetics will require formulation optimization
and may be associated with additional toxicology proﬁles.
Acknowledging how mechanism of action relates to therapeu-
tic window of opportunity is a critical component in the evalua-
tion of clinical potential. For example, application of connexin-
based therapeutics (e.g. ACT1) whose mechanism of action in
wound healing relates to the modulation of inﬂammatory path-
ways would be most efﬁcacious if applied immediately following
injury during initial inﬂammatory responses, where failure to re-
solve these responses leads to abrogation of the repair process
and chronic non-healing states [75]. In radiation exposure, where
atrophy and uncontrolled inﬂammatory responses may occur
months or years later [76,77], therapeutic application during
deﬁnitive care protocols may have the potential to restore tissue
homeostasis.
It is important to recognize that the clinical exploration of other
dermally expressed connexins has been suggested. Cx26 and Cx30
are both upregulated during epidermal regeneration, are much
more strongly expressed in hyperproliferative than in normal
epidermis, and likely play a signiﬁcant role in keratinocyte differ-
entiation [36,78]. These two connexins may form heteromeric
gap junctions with distinct permeability properties [79]. Therapeu-
tic opportunity for targeting Cx26 stems from evidence using
murine psoriasis models where it was found that mice expressing
Cx26 under an Involucrin (keratinocyte-speciﬁc) promoter stalled
the epidermis in a hyperproliferative state and delayed reepitheli-
alization [80]. Importantly, ectopic Cx26 expression increased ATP
release; the authors suggest that decreasing Cx26 levels of epithe-
lialized lesions may offer therapeutic beneﬁt by reestablishing the
epidermal barrier and modulating the skin inﬂammatory response.
2.2. Diabetic wound healing
The established efﬁcacy of the aforementioned Cx43 antisense
and C-terminal mimetic based therapeutics in the context of
wound healing directly translates to subsequent evaluation in
disease states characterized by chronic wounds and connexin
dysregulation. Diabetic wounds are associated with a debilitating
chronic phenotype and often remain refractory to conventional
therapeutic intervention [81]. The onset and progression of diabe-
tes is associated with signiﬁcant alteration in connexin expres-
sion, phosphorylation, functionality, and degradation. These
effects may be linked to extrinsic factors, such as abnormal glu-
cose levels [82], as well as intrinsic factors such as disruption in
proinﬂammatory cytokine or apoptosis-regulating gene expres-
sion [83]. Elevated Cx43 expression and GJ communication has
been reported in diabetic keratinocytes and ﬁbroblasts, respec-
tively [36,84]. In streptozotocin-induced diabetic rat models, epi-
dermal expression of Cx43 and Cx26 is signiﬁcantly
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Following injury, wound edge keratinocytes upregulate Cx43 and
form a thickened bulb of non-migrating cells. Normal wound
healing processes, characterized by the downregulation of Cx43,
are signiﬁcantly delayed and initiate at approximately 48–72 h
post wounding [49]. The mechanistic link between the dysregula-
tion of Cx43 expression/gap junctional intercellular communica-
tion and delayed diabetic wound healing remains to be
deciphered. However, it is likely that Cx43 mediated cell apopto-
sis [85,86], regulation of inﬂammatory signals, growth factors,
pro- or anti-oxidant molecules via the gating or opening of GJ
channels, and Cx43 meditation of immunocompetent cells all
may have roles. Recent evidence using cultured rat glomerular
mesangial cells under high-glucose conditions link the AMPK/
mTOR signaling pathway in regulating Cx43 expression and the
pathogenesis of diabetic nephropathy [87].
It was preclinical studies in the diabetic C57BL/KsJ-m+/+Leptdb
(db+/db+) mouse model that provided initial evidence for the
wound-healing potential of the Cx43 mimetic peptide ACT1 in
the treatment of diabetic skin wounds. As in previous murine mod-
els [64], ACT1 application signiﬁcantly accelerated wound healing
and tempered inﬂammatory responses in diabetic rodents. Simi-
larly, topical application of Cx43asODN has been shown to effec-
tively prevent Cx43 upregulation and keratinocyte clumping in
streptozotocin diabetic rat models following wounding and dou-
bled the rate of reepithelialization [49].
Human trials with ACT1 have solidiﬁed the clinical promise
associated with targeting Cx43 to overcome the resistant healing
phenotype associated with diabetic wounds. In Phase 2 clinical tri-
als, topical application of ACT1 (Granexin™ Gel) to chronic diabetic
foot ulcers resulted in a signiﬁcantly greater reduction in mean
percent wound area as compared to standard of care protocols.
In these trials, therapeutically targeting Cx43 was not associated
with immunological responses, local or systemic adverse events.
Similar trials are currently underway for Cx43asODN (ClinicalTri-
als.gov Identiﬁer NCT01490879). It is important to acknowledge
that knocking out Cx43 in murine models has led to alterations
in testicular gene expression [88] as well hematopoiesis [89], again
reinforcing the need for caution when therapeutically applying
antisense technologies. Additional investigation into the relation-
ship between connexin expression and hypoglycemic drugs, cyto-
kine expression, oxidative environment, and inﬂammatory
responses in the context of diabetic wounds will aid in steps to-
wards FDA approval.
The marked upregulation of Cx43 in the dermis of human
chronic wounds appears to be a feature underlying impaired
reepithelialization and wound healing. Detrimental Cx43 upregu-
lation in dermal ﬁbroblasts has also been described in venous leg
ulcers. In vivo and in vitro targeting of Cx43 and N-cadherin re-
sulted in increased Golgi polarization whilst reducing ﬁbroblast
proliferation and cell adhesion, and inducing cytoskeletal
changes, increased lamellipodia protrusion, and activation of
Rho GTPases [90]. These results suggest a GJ independent role
for Cx43 in the stabilization of multiprotein complexes compris-
ing N-cadherin that are required for cell–cell adhesion and adhe-
sion-dependent actin dynamics. The authors suggest that these
complexes must be broken down to facilitate efﬁcient ﬁbroblast
migration. Similar to application to diabetic ulcers, preliminary
clinical evaluation of the safety and efﬁcacy of both ACT1 and
Cx43asODN in accelerating the healing of chronic venous ulcers
has been encouraging. It is likely that targeting Cx43 in other
chronic wounds that are similarly characterized by chronic
inﬂammation and retarded reepithelialization, including pressure
ulcers, and post-surgical and traumatic ulcers will elucidate addi-
tional therapeutic promise.2.3. Corneal wound healing
Connexin expression, mainly Cx26, Cx30, Cx31.3, Cx37, Cx43,
and Cx50, has been well documented in the human cornea [91].
Notwithstanding the obvious physiological differences with re-
gards to the processes that deﬁne dermal versus corneal wound
healing, the connexin response in these tissues is remarkably sim-
ilar. Despite the cornea being an avascular structure, both the skin
and cornea have a collagenous stroma, and a stratiﬁed squamous
cell epithelium. Furthermore, the cytokines and growth factors in-
volved in wound repair are similar, including IL-1, TNFa, EGF,
PDGF, and TGF-b [92]. Additionally, during wound healing corneal
stromal keratinocytes and skin dermal ﬁbroblasts play equivalent
roles. Following corneal wounding, connexins, including Cx43,
are rapidly downregulated at the migrating wound edge and in
regenerating migrating corneal epithelial cells [93]. Given the sim-
ilarities in Cx43 expression patterns during wound healing in the
epidermis and corneal epithelium, therapeutic extension of conn-
exin targeting agents can be easily justiﬁed. In rat corneal scrape
injury models the over-expression of Cx43 using adenovirus inhib-
ited corneal endothelial wound healing, while knockdown with
Cx43 siRNA or Cx43 antisense sped it up and inhibited endothe-
lial-mesenchymal transition [94], which has important roles in
corneal ﬁbrosis following injury [95]. Clinically, corneal ﬁbrosis
translates to the loss of corneal clarity and visual acuity. Corneal
therapeutics offering accelerated healing in addition to the preven-
tion of ﬁbrosis would be of great value.
In the corneal epithelium, in association with enhancing the
rate of Cx43 decrease following wounding and increasing the rate
of recovery, application of Cx43asODN or the Cx43-based mimetic
peptide ACT1 in rat corneal injury models reduced hyperplasia and
ﬁbrosis [93,96]. The evaluation of endothelial-mesenchymal tran-
sition pathway genes, including keratin 8, keratin 19, and TGFb2,
in in vivo corneal wound healing studies applying ACT1 suggest
that immediately after wounding a transmigration stage of re-epi-
thelialization occurred, rather than the proliferation of cells from
the limbal region. ACT1 treatment of corneal wounds therefore di-
rectly mediates the upregulation of epithelial cell migration [96].
Clinical potential of a Cx43asODN Poloxamer407 gel formulation
hasbeen evaluated in a small study incorporating5patientswith se-
vere non-responsive ocular surface burns. Treated eyeswere associ-
ated with reduced inﬂammation, and recovery of the vascular bed
and limbal reperfusion prior to epithelial recovery [97]. Phase 2 clin-
ical trials evaluating the efﬁcacy and safety of a Cx43asODN formu-
lation in the treatment of persistent corneal epithelial defects are
currently recruiting (ClinicalTrials.gov Identiﬁer NCT01165450).
Effective topical ocular drug delivery of peptide and protein
drugs presents a particular challenge in the formulation of effective
corneal therapeutics. Susceptibility to physical and chemical alter-
ation (i.e. denaturation, aggregation, oxidation, hydrolysis, etc.)
following physiological ﬂuctuations may limit bioabsorption across
the corneal epithelium. In response to this challenge, following ini-
tial efﬁcacy studies outlining the therapeutic potential of ACT1 in
accelerating the healing of corneal wounds, a biocompatible,
sustained, controlled release formulation involving ACT1 loaded
alginate poly-l-ornithine microcapsules has been formulated
[96,98]. This formulation renders the Cx43-based mimetic peptide
resistant to physical and chemical degradation and extends the pep-
tides ocular half-life in order to maintain the peptides integrity
while achieving the appropriate ocular drug concentration. Further-
more, this formulation is associated with prolonged precorneal
retention and controlled ACT1 release. Application of microcap-
sule-based connexin therapeuticswill likelyprove fruitful in a great-
er therapeutic context where microcapsules may be speciﬁcally
engineered to provide targeted delivery.
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corneal wound healing may be particularly relevant in individuals
with pathologies that are directly associated with corneal epithe-
lial defects. Diabetes is associated with a number of corneal com-
plications including reduced barrier function, thickness, corneal
sensitivity (neuropathy), and tear secretion, as well as changes in
endothelial cell morphology and density, and diabetic keratopathy.
In normoglycemic persons, minor epithelial defects rapidly heal;
however, individuals with diabetes present with corneal epithelial
defects that are associated with abnormal corneal re-epithelializa-
tion that remain resistant to conventional therapeutic regimens.
Preclinical studies using the Goto-Kakizaki Type 2 diabetic rat
model and a streptozotocin-induced Type 1 diabetic rat model
have demonstrated the safety and efﬁcacy of a sustained release
ACT1 microcapsule eye drop formulation in signiﬁcantly accelerat-
ing corneal re-epithelialization and regulating anti-inﬂammatory
proteins, including TNFa and the CXCR3 chemokine ITAC following
injury in diabetic rats [99].
Clinical opportunity has been suggested for other corneal
expressed connexins. Cx31.1 forms non-functional channels in
the upper suprabasal and superﬁcial layers of the corneal epithe-
lium and appears to have key roles in regulating apoptotic path-
ways and maintaining corneal homeostasis [100]. Application of
Cx31.1 antisense oligonucleotides in ex vivo rodent and human
corneal models results in decreased epithelial cell apoptosis and
increases in corneal thickness. The mechanism of action is likely
linked to roles for Cx31.1 in the reduction in superﬁcial cell death
and shedding [101]. Additional research investigating the mecha-
nism is required to fully elucidate the clinical potential of targeting
Cx31.1 in the cornea. The evaluation of alternative molecular tools
that are aimed at regulating Cx31.1 activity as opposed to abolish-
ing protein expression may prove beneﬁcial.
2.4. Acute lung injury
Given the relative heterogeneity that is associated with cellular
composition of the lung, it is not surprising that connexins are ex-
pressed differentially depending on cell phenotype/function and
stage of differentiation (reviewed in [102]). Deﬁning connexin
expression in the lung is further complicated by the potential of
coexpressed connexins to (a) form heteromeric gap junction chan-
nels and to (b) ‘personalize’ permeability and gating proﬁles as
required [103]. Connexin dysregulation has been linked to the eti-
ology and progression of a number of lung diseases including acute
lung injury, cystic ﬁbrosis, asthma, and pulmonary arterial
hypertension.
Acute lung injury is associated with the loss of alveolar-capil-
lary membrane integrity, excessive transepithelial neutrophil
migration, release of pro-inﬂammatory/cytotoxic mediators,
impaired arterial oxygenation and ultimate risk of hypoxemic
respiratory failure. During the acute phase of lung injury, in-
creased pulmonary vascular permeability is associated with an
upregulation of Cx43 and Cx46 expression and the downregula-
tion of Cx40 [104,105]. The critical role for Cx43 in promoting
and regulating inﬂammatory signals has been demonstrated in
murine models lacking endothelial Cx43 and in Cx43+/ mice
where Cx43 expression was linked to the propagation of calcium
waves along pulmonary vessels, the promotion of leukocyte adhe-
sion to the vascular surface, and the recruitment of neutrophils to
the alveolar space following lipopolysaccharide (LPS) challenge
[106]. Alternatively, Cx40 prevents neutrophil adhesion and con-
tributes to anti-inﬂammatory signaling pathways. Blockers of GJ
intercellular communication, such as the long-chain alcohol,
heptanol, inhibited the diffusion of endothelial calcium oscilla-
tions along the capillaries induced by pressure elevation in
perfused lung; translating to an increased risk of pulmonaryedema in acute lung injury [107]. These data imply therapeutic
opportunity in regulating the propagation of pro-inﬂammatory
signaling via connexin manipulation from a variety of angles
during acute lung injury.
Anti-Cx43 strategies have been assessed in LPS models of acute
lung injury where intratrachael administration of the Cx43 mi-
metic peptide Gap26 resulted in attenuation of the inﬂammatory
response and reduced neutrophil recruitment from blood circula-
tion to the lungs [105]. Additional therapeutic innovation has
recently been inspired in the suggestion that the protective effects
of Cx-based mimetic peptides in acute lung injury may be medi-
ated in part by decreased ATP release from pannexins [108].
Pannexins are structurally similar but phylogenetically unrelated
to the connexin family and may offer a novel therapeutic strategy
in managing pulmonary inﬂammation.
Alternatively, recent in vivo studies suggest that stabilizing
endothelial and epithelial barriers may be a strategy in the treat-
ment of acute lung injury [109–111]. Small molecule inhibitors
of the calmodulin activated protein kinase, myosin light chain ki-
nase (MLCK), improved outcomes in animal models of acute lung
injury. MLC activation caused cell contraction leading to the forma-
tion of gaps between cells, loosening adherence, and tight junction
dysfunctions, enabling inﬂammatory mediators and infectious
agents to enter the surrounding tissue [112–115]. Furthermore,
modulation of ZO-1 function may have beneﬁcial effects towards
restoring barrier function. ZO-1 phosphorylation has roles in tight
junctional opening in alveolar epithelial cells and the permeability
of the blood-air barrier [112,116].
Therapeutic promise for Cx43 peptide-mimetics in the treat-
ment of acute lung injury has recently been investigated. ACT1
treatment of bronchial epithelial cells and lung microvascular
endothelial cells exposed to LPS and hydrogen peroxide, key stress-
ors associated with acute lung injury induction and ventilator com-
plications, stabilized tight junction integrity and improved
transepithelial electrical resistance (Atkinson et al., 2014, in prep).
In an in vivo lethal murine LPS-induced acute lung injury model,
pre-treatment of mice with ACT1 signiﬁcantly improved survival
rate as compared to untreated controls. In a sub-lethal murine
model, intranasal pre-treatment of mice with ACT1 30 min prior
to LPS exposure resulted in a signiﬁcant reduction in neutrophil,
macrophage, and albumin in lavage ﬂuids, improved lung pathol-
ogy scores, and reduced KC/MIP-1 chemokine levels 18 h post
LPS instillation as compared to control treated animals. Transla-
tional extension of these observations suggests that ACT1 therapy
in acute lung injury may contribute to a reduction in inﬂammatory
cell inﬁltration, ﬂuid and pathogen transportation. ACT1 mediated
regulation of ZO-1 binding, Cx43 phosphorylation and hemichan-
nel activity likely all have roles that will provide further insight
into therapeutic opportunity.
3. Potential for connexin-based therapeutics in the heart
Like the transient and deﬁned expression pattern of connexins
during wound healing, studies of humans with ischemic heart dis-
ease and matching animal models reveal changes in connexin
expression and subcellular localization in the injured heart [117–
120]. These similarities underlie the translatability of connexin-
based therapeutics from the skin to the heart [121]. The heart de-
pends on the spatial order of GJ organization, where connexins
transmit and synchronize the electrical impulse that initiates car-
diomyocyte contraction from beat to beat. The three main isoforms
expressed in the heart are Cx40, Cx43, and Cx45 [122]. Cx43 is the
most widely distributed in the heart, being the primary if not only
isoform expressed in ventricular myocytes [117,118], where it lar-
gely localizes to the intercalated disk (ID; the end-to-end abutment
of two connected cardiomyocytes). As such, this section will focus
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cardiopathologies.
A hallmark of cardiac pathology is a poorly understood process
termed GJ remodeling [117–120]. In general, remodeling describes
a process by which GJs are redistributed from the ID to the lateral
borders of cardiomyocytes, and this phenomenon is common to
diseases ranging from ischemic infarction to congestive heart
failure [123]. The form that lateralized Cx43 takes – intercellular
channels or hemichannels – is currently a matter of speculation,
but either situation would likely be arrhythmogenic [6].
Speciﬁcally, in one case, lateralized GJs would alter anisotropic
conduction, providing a substrate for arrhythmia [124,125]. In
the other case, under pathological conditions Cx43 hemichannels
open, promoting cardiomyocyte cell death [126].
A separate but related issue is the ﬁbrosis and scarring that
come with end-stage heart failure and myocardial infarction,
respectively. These phenomena may affect conduction in the heart
in a number of ways. First, ﬁbrosis that occurs due to aging creates
collagenous septa between atrial myocytes that reduce coupling
and are proarrhythmogenic [127]. A similar situation plays a role
in arrhythmia due to heart disease – ‘‘replacement’’ ﬁbrosis serves
to maintain the structural integrity of the heart as cells die, but
interstitial collagen deposition impairs conduction [128]. In the
case of infarction, the myocardium becomes necrotic, eliciting an
innate inﬂammatory response followed by scarring and ﬁbrosis
of the infarct border zone myocardium [121]. The ﬁbrotic border
zone becomes a substrate for reentrant arrhythmia due to a com-
bination of scarring, and structural remodeling of both myocytes
bundles and GJs [129].
Connexins are involved in these processes not only through al-
tered conduction, but also, as in the realm of wound healing, via
the role they play in inﬂammation and scarring. ATP released from
connexin hemichannels in the vasculature and damaged myocytes
targets neutrophils to the infarct site [74,130]. Subsequently, con-
nexins play a key role in monocyte-endothelial cell adhesion [131],
ﬁbroblast migration and differentiation to myoﬁbroblasts [40,132],
and collagen deposition [38,133]. Additionally, recent develop-
ments suggest that GJs formed between myocytes and ﬁbroblasts
play both physiological and pathological roles in conduction and
arrhythmogenesis. For an excellent current review of that subject
we refer the reader to the work of Kohl and Gourdie [134].
3.1. To the heart of it: connexin targeting cardio-therapeutics
It is into this complex mix that connexin-based therapeutics
enter the fray. Treatments that enhance GJ communication might
improve slowed conduction, but could also potentiate alternative
conduction pathways (e.g. myocyte-ﬁbroblast connections), pro-
mote the bystander effect, or enhance hemichannel ATP release.
Conversely, treatments that gate hemichannels closed are often
the same drugs that inhibit GJ communication. Currently, no conn-
exin-based therapeutics are in use in the clinic for the treatment of
either arrhythmia or heart disease in general, but there are several
in the pipeline, many with published results in animals, and a
multitude of potential targets.
Most of the connexin-based therapeutics are peptides, a subset
of which are Cx43-mimetic peptides. Of the non-mimetic peptides,
there appear to be 2 classes [135]: those based on antiarrhythmic
peptide (AAP) – an endogenous peptide isolated from the bovine
atrium [136]; and those based on RXP-E – a peptide identiﬁed by
phage display to bind the Cx43 C-terminus containing the amino
acid sequence R-X-P where X is any amino acid [137]. The AAP
derivatives include HP-5, AAP10, ZP123 (the more stable D-amino
acid analogue of AAP10, aka rotigaptide and GAP-486), and
GAP-134 (a dipeptide derivative of ZP123, aka ZP1609 and dane-
gaptide) [135]. Studies in animals show that these peptides haveantiarrhythmic properties in a variety of models [138–142], and
most recently GAP-134 has been shown to reduce infarct size in
a porcine left anterior descending (LAD) artery occlusion model
of myocardial infarction [143]. Phase II clinical trials were initiated
with ZP123 (ClinicalTrials.gov Identiﬁers NCT00137293 and
NCT00137332), but were terminated to prioritize clinical trials
for GAP-134 (NCT00510029, NCT00543946, and NCT00783341)
[135]. ZP123 showed promising results, and GAP-134 will likely
prove to be an equally good antiarrhythmic with the added beneﬁt
of oral bioavailability [135].
Mechanistic studies have indicated a mode of action involving
increased GJ communication. Clarke et al. demonstrated that
ZP123 increases GJ communication [144], and although there is
no direct evidence of improved GJ intercellular communication
with GAP-134 treatment, GAP-134 did prevent conduction velocity
slowing in a canine pericarditis model [145], indicating that the
peptide does have a positive effect on communication. Perplex-
ingly, while AAP10 enhanced Cx43 hemichannel-mediated ATP re-
lease in cultured cardiomyocytes [130], both GAP-134 and ZP123
reduced dye uptake in C6 glioma cells [142]. Whether ZP123 and
GAP-143 inhibit or enhance hemichannel function in myocytes re-
mains to be seen, but cell type-speciﬁc responses may be at the
‘‘heart’’ of the matter. The reason for this comes down to the gen-
eral mode of action for AAPs. As reviewed by De Vuyst et al. [135],
these peptides activate an unknown GPCR that in turn activates
PKCa. In myocytes, other PKC isoforms, such as PKCe, may be
responsible for differential effects [135].
The RXP peptides also show promise, although no published
animal work has been done at this point. RXP-E, CyRP-71 (a cyclic
variant of RXP-E), and ZP2519 (a peptide based on the minimum
core active structure of the RXP peptides) all have been demon-
strated to prevent acidiﬁcation-induced closure of gap junctions
(a situation encountered during ischemia [146]) [137,147,148].
Furthermore, RXP-E prevented action potential propagation block
in monolayers of neonatal rat ventricular myocytes [149]. Unlike
the AAPs, the RXP peptides function through direct interaction
with the Cx43 carboxyl-terminus [137,149], in the region respon-
sible for pH-dependent dimerization [150]. Further work will be
needed to determine if the RXP peptides will be beneﬁcial as car-
dio-therapeutics.
Similarly, all of the Cx43-mimetic peptides function by direct
interaction with Cx43. The best characterized of these peptides
are the extracellular loop peptides, Gap26 and Gap27. Studies on
cardiac function with Gap26 and Gap27 have been conducted in
cultured cells and animals. In culture, Gap26 has been demon-
strated to block hemichannel-mediated dye uptake and signiﬁ-
cantly improve cell viability in cardiomyocytes exposed to
simulated ischemia [126]. In Langendorff-perfused rat hearts
subjected to LAD occlusion, addition of Gap26 reduced infarct size
by 50% [151], and application of either Gap26 or Gap27 reduced
infarct size up to 61% in an in vivo rat model of myocardial infarc-
tion by LAD occlusion [152]. These results may seem paradoxical
given that Gap26/27 also affect intercellular channel formation,
but in these studies the peptides were delivered as a single bolus
injection, suggesting they were only present in the heart long
enough to block hemichannels. That being said, it is important to
note that caution needs to be used, especially in the heart, when
applying blockers of GJ channels or knocking down connexin
expression. Arrhythmia is a likely outcome of potent GJ inhibition,
as suggested by work showing that cardiac-speciﬁc deletion of
Cx43 causes sudden arrhythmic death in mice by 2 months of
age [153].
As the above discussion suggests, the dichotomy between
blocking hemichannels vs GJ channels is a controversy that is espe-
cially relevant in the heart. As discussed elsewhere in this article,
blocking GJ channels can have beneﬁcial effects in injury by
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may also be true in the heart, as it has been found that mice with
heterozygous deletion of Cx43 display reduced infarct volumes
[154]. However, the trade-off of reduced GJ coupling for decreased
bystander effect may not pay – mice heterozygous for Cx43 also
display conduction slowing [155]. Pharmacological inhibition of
connexins also results in conduction slowing [156,157], suggesting
that connexin blockers should only be applied cautiously, and sys-
temic administration should be avoided.
Gap19 is another Cx43-mimetic peptide that shows promise as
a cardio-therapeutic. It is a non-apeptide derived from the larger
L2 domain of the Cx43 cytoplasmic loop [158]. Previous studies
showed that a full L2 peptide fused to the membrane-permeable
TAT sequence maintained hemichannels in a closed state when
subjected to mechanical stimulation by binding to the Cx43 car-
boxyl-terminus [159]. Unlike the TAT-L2 peptide, Gap19 itself is
membrane permeable due to a combination of its small size and
the inclusion of the KKFK membrane translocation motif [158]. In
a comprehensive study, Wang et al. have showed that Gap19 also
binds to the Cx43 C-terminus, speciﬁcally inhibits Cx43 hemichan-
nels and ATP release without affecting GJ communication, in-
creased cell viability of cardiomyocytes exposed to simulated
ischemia, and reduced infarct size in mice subjected to LAD ligation
[158]. These results suggest that Gap19 may be an ideal candidate
to treat myocardial infarction.
The last of the mimetic peptides to be discussed is ACT1. As dis-
cussed above, it is a mimetic of the Cx43 carboxyl-terminus that
blocks Cx43/ZO-1 interaction [63]. Importantly, it has been shown
that Cx43/ZO-1 interaction is enhanced in ischemic and dilated
cardiomyopathy in association with an increase in the relative
amount of non-junctional (hemichannel) Cx43 as compared to
Cx43 in GJs [160]. It is also important to this discussion to reiterate
that the effect of ACT1 on GJs is to increase the number of intercel-
lular channels at the expense of hemichannels, consequently
enhancing GJ communication while simultaneously reducing
hemichannel function [25]. These effects were associated with a
structure adjacent to the GJ called the perinexus where hemichan-
nels reside ([6,25]; also, see Fig. 1). Recent work demonstrates that
Cx43 interacts with the voltage-gated sodium channel Nav1.5 (the
channel responsible for the upstroke in the cardiomyocyte action
potential) in the perinexus [161], where it may play a role in con-
duction [162]. Preliminary work indicates that this interaction may
be enhanced by ACT1 [163], suggesting that ACT1 has effects on
cardiomyocytes through multiple mechanisms.
In vivo work with ACT1 has demonstrated a positive effect on
the injured myocardium. O’Quinn et al. demonstrated that appli-
cation of ACT1 in a mouse model of cryoinfarction reduced Cx43/
ZO-1 colocalization and GJ remodeling in the infarct border zone,
and signiﬁcantly reduced the severity of pacing-induced arrhyth-
mias in isolated perfused hearts [66]. In addition, ACT1 enhanced
phosphorylation of the S368 residue (pS368) on the Cx43
carboxyl-terminus. Cx43 phosphorylated on S368 may help to
preserve Cx43 at the ID [66,67,119]. pS368 may have also had a
beneﬁcial effect on preservation of border zone myocytes as
pS368 has been shown to enhance selective permeability [119],
which has been suggested to create a distinct communication
compartment [45] that might insulate border zone myocytes from
the bystander effect and prevent them from becoming a substrate
for arrhythmia.
No clinical studies assessing the cardioprotective effects of
ACT1 have yet been conducted. However, as discussed above, pre-
clinical and clinical trials demonstrate that ACT1 was well toler-
ated in animals and was not associated with any adverse events
or immunogenecity. This suggests that ACT1 may be an ideal
candidate for repurposing as an antiarrhythmic.In addition to the peptide-based treatments, genetic engineer-
ing approaches have recently been explored in animal models. Bik-
ou et al. induced atrial ﬁbrillation in a porcine model by atrial burst
pacing, and found that Cx43 protein content was reduced, leading
to a deterioration in cardiac function [164]. Adenoviral Cx43 gene
transfer by injection into the atria followed by epicardial electro-
poration resulted in increased Cx43 protein levels and prevention
of reduced cardiac function during burst pacing. Similarly, Igarashi
et al. introduced Cx43 and Cx40 to the atria of Yorkshire swine by
gene painting of adenoviral vectors, and atrial ﬁbrillation was in-
duced by burst pacing [165]. Unpaced animals displayed no
changes in atrial conduction, but animals subjected to atrial ﬁbril-
lation displaced reduced and lateralized Cx43 expression that
could be restored by gene therapy. Importantly, expression of both
Cx43 and Cx40 improved conduction and prevented atrial ﬁbrilla-
tion [165]. Whether connexin gene therapy will make it to the
clinic remains to be seen, but these studies provide an encouraging
start.
A number of other therapeutic targets are implicated by basic
science research. The Cx43 carboxyl-terminus has a number of
protein modiﬁcation and protein interaction sites that regulate
its life-cycle and channel gating [67]. Inhibition or enhancement
of a number of the protein interaction or modiﬁcation events
may prove to be beneﬁcial in the treatment of cardiac pathologies.
However, this is a subject far too broad for the limited scope of this
article, and we refer the reader to the following reviews for a full
discussion: [45,67,166–168]. Nonetheless, a few recent discovers
are noteworthy. Dunn and Lampe showed that Akt phosphorylates
Cx43 on S373, which in turn leads to dissociation of Cx43/ZO-1
interaction and the formation of larger GJs [169], suggesting that
this phosphorylation site regulates the same molecular switch as
ACT1 [25]. Conversely, Src phosphorylation of S279 and S282 have
been shown to mediate Cx43 endocytosis [170,171], indicating
that targeting of Src-mediated Cx43 phosphorlation may prevent
injury-mediated endocytosis of GJs. Supporting this concept, Mes-
troni and Nguyen review a number of studies in which Src inhibi-
tors show antiarrhythmic properties [172], and Gangoso et al.
describe a Cx43/Src interaction inhibiting peptide (PEP-1 and
PEP-2) that reverses the glioma stem cell phenotype [173]. Taken
together, these studies suggest point to S373, S279, and S282 as
potential targets of Cx43-based molecular therapeutics.
On the other hand, targeting Cx43 trafﬁcking to the membrane
may also be an effective way to combat Cx43 dysregulation in car-
diac pathology. The Shaw lab demonstrated that Cx43 trafﬁcking to
the membrane is dependent on both microtubules [174], and actin
[175], and that these delivery systems are both disrupted during
ischemia [175,176], indicating therapeutic potential. Excitingly,
recent work by Smyth and Shaw determined that multiple car-
boxyl-terminal isoforms of Cx43 occur in the heart, and that these
truncated Cx43 isoforms are the result of internal translation of
Cx43 mRNA [177]. Importantly, it was found that expression of a
20 kDa isoform in particular is necessary as a chaperone to trafﬁc
Cx43 to the cell surface [177]. Treatment with synthetic versions
of these endogenous peptides, or gene therapy approaches that en-
hance their expression, may turn out to be effective therapies to
combat the reduced Cx43 expression that is common to cardiac
disease.
4. Potential for connexin-based therapeutics in the central
nervous system
Twelve years following the 1952 discovery of GJs in electrical
coupling between heart cells, electrical coupling between glial cells
was noted in the leech central nervous system [178]. Given that
the human central nervous system (CNS) is one of the most
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ture, arrangement, and interconnectedness the clinical potential of
connexin-based CNS therapeutics demands extensive discussion
that extends beyond this review. As a starting point, and in terms
of the brain’s interconnections, it is the neuronal synapses that are
usually called to mind – the human brain contains about 85 billion
neurons [179], and 150 trillion synapses [180]. GJs are formed be-
tween neurons where they function in synaptogenesis, neuronal
differentiation, migration, and neural circuit formation and matu-
ration during development, and in mature brains it is thought that
they modulate synchronized oscillatory activity [181].
What also needs to be appreciated, is that the brain contains a
number of supporting glial cells approximately equal to the num-
ber of neurons [179], and these cells are also heavily intercon-
nected by GJs [182]. In particular, astrocytic GJs form between
astrocytes at blood vessels and synapses where they are thought
to regulate the blood–brain barrier and provide a homeostatic
environment for neurons, respectively [183]. Furthermore, a num-
ber of physiological roles for hemichannels in the CNS have
emerged, from calcium wave propagation [184] to ephaptic cou-
pling in the retina [185]. Recently, astrocytic processes terminating
at synapses have been speculated to form a ‘‘tripartite synapse’’
with astrocytes modulating and even participating in synaptic
transmission through the release of gliotransmitters [186].
Whether connexins are a component of the tripartite synapse
remains to be seen.
Within this context, a general paradigm appears to have arisen
for the response of connexins to injury in the CNS. Speciﬁcally,
astrocytic GJs and hemichannels generally appear to be oppositely
regulated by injury signals - proinﬂammatory cytokines, ROS/RNS,
and ATP [182]. In the setting of ischemia, opening of astrocyte
hemichannels and further release of ATP [182] and glutamate
results in neuronal cell death directly through opening of neuronal
pannexin channels [187], and recruitment of inﬂammatory leuko-
cytes that exacerbate cerebral damage [188]. Importantly, these
processes, and changes in connexin channel function and expres-
sion in general, may also be integral to a number of diseases
including Alzheimer’s, Huntington’s, and Parkinson’s disease
[189,190]. With this in mind, connexins – Cx43 in particular, as
it is the primary connexin expressed in astrocytes [189] – are a
vital target for a new class of connexin-based therapeutics in the
CNS.
4.1. Connexin targeting CNS therapeutics: proceed with caution
Before entering into a discussion of connexin-based CNS thera-
peutics, it must be acknowledged that pharmacological blockers of
GJ channels have been associated with adverse neurological ef-
fects. For example, meﬂoquine is an antimalarial formerly mar-
keted in the US as Lariam. It is routinely used in connexin basic
science studies as a channel blocker (e.g. [25]), but has also been
shown to have the following clinical psychiatric side effects: anxi-
ety, panic attacks, paranoia, persecutory delusions, dissociative
psychosis, and anterograde amnesia [191]. A case study of the ex-
treme hallucinogenic and amnesic effects of meﬂoquine has re-
cently been popularized by David S. MacLean in an episode of
This American Life (http://www.thisamericanlife.org/contribu-
tors/david-maclean) and his book, The Answer to the Riddle Is Me
[192]. These effects appear to result from blocking of GJs between
inhibitory neurons in the limbic system, thus preventing synchro-
nization. Along these same lines, an extracellular loop mimetic
peptide was shown to have beneﬁcial effects following global cere-
bral ischemia in near-term fetal sheep at low doses, but at high
doses resulted in cell swelling, acidosis, and increased mortality
[193]. These results suggest that, like the heart (see previous sec-
tion), in the brain blocking hemichannels may be beneﬁcial inpathological scenarios, but GJ blockade will likely have deleterious
effects. Therefore, we recommend caution in applying connexin-
based therapeutics in the nervous system.
To our knowledge, only one clinical study has been performed
involving connexin-based therapeutics in the CNS. Tonabersat is
a novel benzoylamino benzopyran compound, that has been
shown to block GJs [194]. Pre-clinical animal trials have shown
that it does not display adverse effects in the heart or CNS, even
at high doses, but clinical trials reported dizziness, nausea, vertigo,
somnolence, paraesthesia, abdominal pain and palpitation in
patients, and in one study cardiovascular effects were noted in
several patients [194]. Despite these negative effects, Tonabersat
was effective in relieving migraine headaches in two of the three
clinical trials [194].
A number of animal studies have been performed that also
highlight connexins as a viable drug target. Initial studies with
Cx43 antisense in pluronic gel showed that application to the
spinal cord of rats achieved a rapid, long-lasting knockdown of
Cx43 [195]. In later work by the same group it was found that
application of Cx43 antisense in two different models of spinal
cord injury (compression and partial transection) reduced astrogl-
iosis, vascular permeability and neutrophil inﬁltration, and
improved performance in locomotion tests [196]. Preliminary data
using a biodegradable patch formulation of the Cx43-based ACT1
peptide has shown promise in neuronal preservation, and reduced
astrogliosis and microgliosis in a rat spinal crush injury model.
More recently, Yoon et al. showed that application of Cx43
antisense to organotypic brain slice cultures improved neuronal
survival and maintained normal cell and organ morphology at
14 days in culture compared to controls [197]. Taken together,
these data indicate that Cx43 participates in neuronal cell death
and recruitment of leukocytes in CNS injury, and that Cx43 knock-
down by antisense is an effective remedy.
Work by two separate groups using a weight-drop model of
spinal cord injury in transgenic mice with Cx43 deletion support
these ﬁndings. Speciﬁcally, Chen et al. found that Cx43 transgenic
mice subjected to spinal cord injury displayed less neuropathic
pain in association with reduced astrogliosis [198]. In an indepen-
dent study, Huang et al. generated spinal cord injury by weight-
drop in Cx43 deletion mice and found that ATP release, astrogliosis
and microglial activation, and lesion size were all reduced while
motor recovery was signiﬁcantly improved compared to controls
[199]. These data suggest that Cx43 hemichannel mediated ATP
release is a critical factor in injury and recovery in CNS damage.
Along these lines, a homologue of the connexin mimetic peptide
Gap27 has been shown to have beneﬁcial effects in CNS injury. In
an organotypic hippocampal slice model of epileptiform lesion,
low concentrations (5–100 lM) of the peptide blocked cell death
during exposure to bicuculline methochloride (BMC; a competitive
GABAA receptor antagonist used to induce the lesion), while high
concentrations (500 lM) exacerbated cell death [200]. Conversely,
during recovery from BMC the high concentration of the peptide
was the most effective at reducing cell death indicating that hemi-
channel mediated injury in the CNS is most prominent during the
insult itself, but that GJ communication has a bystander effect dur-
ing recovery periods (e.g. reperfusion). Similarly, systemic applica-
tion of the Gap27 homologue after ischemic retinal injury induced
by high intraocular pressure resulted in increased retinal ganglion
cell survival, and reduced vascular leakage and astrogliosis com-
pared to controls [201]. Importantly, in vitro assays of endothelial
survival and hemichannel function following hypoxia showed that
connexin channel blockers, including the mimetic peptide, reduced
hemichannel activity and increased cell viability supporting the
concept of hemichannel mediated injury.
Connexin hemichannels and GJ channels also appear to play a
large role in perinatal ischemic brain injury. Early work by de
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hippocampal slice cultures subjected to oxygen-glucose depriva-
tion, or to rat pups subjected to intrauterine hypoxia–ischemia,
reduced neuronal death and long-term neuronal damage respec-
tively [202]. As discussed above, it has been shown that low doses
of extracellular loop peptide were found to be beneﬁcial in a fetal
sheep model of ischemic brain injury [193]. Speciﬁcally, EEG power
was signiﬁcantly higher following ischemia in the low dose peptide
group both immediately following ischemia, and 5 days onward
post ischemia. These results were supported by later work by the
same group, but interestingly, it was found that the peptide was
only effective when applied 90 min after ischemia, but not during
ischemia, suggesting that timing of treatment is as much an issue
as dosage with connexin-based therapeutics [203].
Non-peptide connexin targeting pharmacological treatments
may also have therapeutic application in the CNS. In one instance,
quinine (a Cx36-speciﬁc channel blocker [204]) was applied to the
retina after mechanical trauma inﬂicted with a 28 gauge needle
[205]. In treated retinas, reductions in retinal cell death were
associated with caspase downregulation. Interestingly, the broad-
spectrum connexin channel inhibitor carbenoxelone was far less
effective in blocking cell death and caspase downregulation. Given
that Cx36 is a primarily neuronal connexin isoform [181], these
results suggest that a neuron-to-neuron bystander effect is an
important factor in retinal neurodegeneration.
Future directions for connexin-based therapeutics are sug-
gested by the basic science literature. ZO-1 has been found to colo-
calize and coimmunoprecipitate with Cx47 (an isoform expressed
in oligodendrocytes) [206] and Cx36 [207] in the mouse brain,
colocalize with Cx36 in the monkey retina and the perinexus of
Cx50 and Cx57 in the rabbit retina [208], and colocalize and coim-
munoprecipitate with astrocytic Cx30 and Cx43 [209]. Importantly,
pulldown assays showed that Cx47 [206] and Cx30 [209] interact
with the second PDZ domain of ZO-1 (as does Cx43 [210]), while
Cx36 interacts with the ﬁrst PDZ domain [207]. These data suggest
that ZO-1 may regulate glial cell GJs in a similar manner to that
described for Cx43 in which ZO-1 limits the rate of hemichannel
accrual into GJ plaques [25]. If this is the case, then peptides that
inhibit Cx43/ZO-1 interaction, such as ACT1, may prove to also
have beneﬁcial effects in CNS injury by limiting hemichannel-
mediated neurodegeneration.
5. The connexin cancer conundrum
At about the same time that GJs were being described in the
leech CNS, a critical role for connexins, GJs, and GJ intercellular
communication in tumorigenesis and/or cancer intravasion and
extravasation was recognized [211]. Initial expression and func-
tional analyses deﬁned connexins as putative tumor suppressors
and restoration of depressed connexin expression and GJ intercel-
lular communication inhibits tumor cell growth [211–215]. In a
seemingly paradoxical twist, it is now evident that connexins are
‘conditional tumor suppressors’ and have additional roles in can-
cers that are type and stage speciﬁc and may be regulated through
upstream phosphorylation events or may be entirely independent
of GJ intercellular communication [214,216–221]. The differential
and dynamic role that connexins have in cancers is extensive and
has been the subject of recent reviews [212,222].
Therapeutic opportunity has been suggested in harnessing the
bystander effect, whereby cells transmit signaling moieties to their
neighbors through GJ intercellular communication. Such an
approach suggests the ability to amplify therapeutic efﬁcacy by
selectively targeting a subset of tumor cells that serve to pass-on
cytotoxic signals. Given that changes in connexin levels may
directly translate to changes in the efﬁcacy of the bystander effect,
modulating connexin expression has become a successful strategyin ‘‘suicide gene therapy’’. In suicide gene therapy, also termed
gene-directed enzyme prodrug therapy, intratumoral delivery of
suicide genes that facilitate the activation of speciﬁc prodrugs into
their cytotoxic effector derivatives, is enhanced by simultaneously
using inducers and stabilizers of GJ intercellular communication.
Transfection of Cx32 genes simultaneously with the herpes-
simplex virus-derived thymidine kinase (HSVtk), which converts
ganciclovir (GCV) into GCV-monophosphate whose subsequent
phosphorylation yields the toxic pro-apoptotic metabolite, GCV-
triphosphate, revealed cytotoxicty in HeLa cells [223]. Therapeutic
efﬁcacy of these types of approaches has been challenged by the
rate-limiting steps associated with phosphorylation-mediated
activation, limited cytotoxicity in slow-growing tumors, poor
biochemical proﬁles that limit application (poor lipophilicity pre-
vents crossing of the blood–brain barrier), and necessity to use at
systemically dangerous dosing levels. Recent attempts at novel
enzyme prodrug systems have involved catalytically enhancing
variants of human thymidylate kinase, where pannexin1 was sug-
gested to form the functional GJ that mediated bystander killing
events [224]. Potential to harness the bystander effect extends to
radiation protocols where the transmission of apoptotic signals
and redox active molecules may diffuse from irradiated to
non-irradiated cells [225], as well as in chemotherapeutic, immu-
notherapeutic, or hormonal therapies, where connexin expression
and GJ communication potentiates tumor sensitivity and therapeu-
tic efﬁcacy [226–228]. Alternatively, the bystander effect can be
incorporated in strategies that are aimed at targeting the tumor
microenvironement, where for example, Cx43 and Cx26 GJs
formed between endothelial and tumor cells can be used to facili-
tate the elimination of endothelial cells by cytotoxic T lympho-
cytes, thus preventing tumor progression [229,230]. An elegant
and promising approach in the treatment of gliomas has been sug-
gested recently in research using cisplatin loaded nanogels conju-
gated with monocloncal antibodies against the extracellular loops
of Cx43 and BSAT1, where nanogel treatment signiﬁcantly in-
creased the median survival of rats in an experimental model of
glioma [231].
The clinical potential of restoring connexin expression is
evident in the number of research publications proposing that
targeting the transcriptional, translational or posttranslational reg-
ulation of connexins in cancer may have therapeutic potential
[212,222,232]. Forced expression of Cx26 and Cx43 in prostate can-
cer cells using recombinant adenoviral constructs showed efﬁcacy
in enhancing cell sensitivity to doxorubicin treatment and
TNFa-induced apoptosis, respectively [233]. The efﬁcacy of HDAC
inhibitors has been linked to global affects on GJ expression and in-
creases in GJ communication [234]. Therapeutics that target the
kinases that mediate connexin phosphorylation, especially with re-
gards to Cx43 [45], present an alternative strategy. Treatment of
colon cancer cells with the plant ﬂavenoid, kaempferol, enhanced
endogenous Cx43 expression and phosphorylation, while post-
transcriptional regulation of GJs through internal ribosomal entry
site-dependent synthesis presents an alternative approach to
restoring connexin expression [235,236]. Taken together, these
studies suggest that a general strategy for combating cancer
tumorigenesis and metastasis may be the enhancement of Cx43
GJ function.
Clinical trials focusing on the validation of enzyme/prodrug
gene therapy prove therapeutic potential via the bystander effect.
These include clinical Phase 1 and 2 studies involving adenovirus
mediated delivery of HSVtk combined with GCV in high grade
gliomas as well in prostrate cancer patients [237,238]. These stud-
ies addressed safety, toxicity, and gene delivery issues but missed
the mark in terms of deciphering the anti-tumor effects of connex-
ins. What is largely lacking is correlation of these studies to the for-
mation of GJ and connexin expression. Furthermore, there are no
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connexin-based cancer therapeutics. This is likely the result of
studies that reveal the context-dependent effects of connexins in
cancers. Talhouk et al., recently completed a series of studies in
breast cancer cell lines that reveal the context-dependent tumor
suppressor effects of Cx43 expression with regards to culture
conditions and the assembly of GJ complexes with a-catenin,
b-catenin, and ZO-2 [239]. Furthermore, the cautionary tale associ-
ated with connexin modulation involves acknowledging the effects
of the intervention in terms each of the stages involved in cancer
progression. Studies aimed at deﬁning the functional involvement
of connexin hemichannels in cancer cell migration and metastasis
are needed. Given the complexities associated with deﬁning conn-
exin mechanism as it relates to tumor type, microenvronment, and
stage, there are signiﬁcant questions that need to be asked and an-
swered prior to the approval of the ﬁrst targeted connexin-based
cancer therapeutics.
6. Conclusion and thoughts on the future
The pathways that drive the onset and progression of disease
reﬂect the combined effects of genetic susceptibility, environmen-
tal stimuli, and hormonal and physiological cues from other organ
systems. Given that all these pathways can be linked in some form
or another to connexin regulation or dysregulation it is not surpris-
ing that the therapeutic opportunity in targeting connexins is
expansive. The topics that were not addressed in this review in-
clude immunological disorders, hearing loss, and gastrointestinal
diseases, and are by no means of less clinical importance. Further-
more, therapeutic opportunity in the roles and functions of Cx43 in
germ cell development and spermatogenesis, in coordinating activ-
ities occurs in the smooth-muscle cells of the uterine wall, and in
developmental situations such as breast tissue in pregnancy and
lactation when there are surges in the levels of speciﬁc GJ proteins,
are exciting, relatively unexplored therapeutic avenues. Of addi-
tional clinical interest is the potential utility of connexins as bio-
markers. Cx43 expression has been linked to lower early
recurrence rates and better prognosis in patients with hepatitis
B-related hepatocellular carcinoma after radical hepatectomy
[240].
While the success of small peptide connexin therapeutics, such
as ACT1, is undeniable, these peptides are often associated with
short half-lives due to rapid degradation and require chemical
modiﬁcation or packaging technologies to enhance bioavailability,
speciﬁcity and pharmacological efﬁcacy. To enhance peptide sta-
bility in the body the addition of synthetic side chains may prove
fruitful. Phosphodiester modiﬁcations involving replacing a non-
bridging oxygen by a sulfur atom in the backbone of connexin anti-
sense or missense oligodeoxynucleotides may protect compounds
from nuclease degradation, enhance cellular uptake and increase
their efﬁcacy as target-speciﬁc agents [241]. Adenoviral ap-
proaches geared at the development of viral-based vectors aimed
at providing a continuous secretion of small peptide connexin
mimetics offer opportunity for the long-term expression of new
genes in human cells at high efﬁciency without causing genetic
mutation or strong immune reactions. The search for effective
non-peptide analogs of the connexin mimetic peptides may prove
to be a fruitful new avenue for rational drug design. Alternatively,
gene editing, where connexin genes may be targeted at speciﬁc
sites in the genome of cells, may offer a future therapeutic strategy.
Another strategy yet to be fully investigated is the therapeutic
application of non-coding RNAs (microRNAs). Cx43 is targeted by
speciﬁc microRNAs and modulation of microRNA function may
have potential in variety of disorders. Given the ubiquitous, tran-
sient, and complex nature of connexin expression, additional drugoptimization strategies need to address concerns with regards to
selectivity, stability, and off-target effects.
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